Salix acquisition values Santarus portfolio, sales force at $2.6bn
This article was originally published in Scrip
Executive Summary
The $2.6bn purchase of Santarus will do more for Salix Pharmaceuticals than expand its revenue base with a slate of marketed products and a pipeline of new drugs.